Jaime Toral López

Jaime Toral López

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Gene
Verified
Journal Article
Closed access
JLJaime Toral López
Jaime Toral López
LGLuz Maria Gonzalez-Huerta
Luz Maria Gonzalez-Huerta
SCSergio A Cuevas-Covarrubias
Sergio A Cuevas-Covarrubias

23 March 2018 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
JLJaime Toral López
Jaime Toral López
LGLuz M. González‐Huerta
Luz M. González‐Huerta
MCMónica Martín‐Del Campo
Mónica Martín‐Del Campo
OMOlga Messina‐Baas
Olga Messina‐Baas
SCSergio A. Cuevas‐Covarrubias
Sergio A. Cuevas‐Covarrubias

1 February 2014 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
JVJuan Manuel Valdes-Miranda
Juan Manuel Valdes-Miranda
JSJose Ramon Soto-Alvarez
Jose Ramon Soto-Alvarez
JLJaime Toral López
Jaime Toral López
LGLuz González-Huerta
Luz González-Huerta
APAdrian Perez-Cabrera
Adrian Perez-Cabrera
SCSergio Cuevas-Covarrubias,
Sergio Cuevas-Covarrubias,

1 April 2008 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JLJaime Toral López
Jaime Toral López
LGL.M. González-Huerta
L.M. González-Huerta
SCS.A. Cuevas-Covarrubias
S.A. Cuevas-Covarrubias

18 December 2015 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
ECEtzalli P. Linares Chávez
Etzalli P. Linares Chávez
JLJaime Toral López
Jaime Toral López
JMJuan M. Valdés Miranda
Juan M. Valdés Miranda
LHLuz M. González Huerta
Luz M. González Huerta
ACAdrian Perez Cabrera
Adrian Perez Cabrera
SCSergio Alberto Cuevas Covarrubias
Sergio Alberto Cuevas Covarrubias
Jacobsen syndrome (JBS) is an uncommon contiguous gene syndrome. About 85-92% of cases have a de novo origin. Clinical variability and severity probably depend on the size of the affected region. The typical clinical features in JBS include intellectual disability, growth retardation, craniofacial dysmorphism as well as craniosynostosis, congenital heart disease, and platelet abnormalities. The proband was a 1 year/3-month-old Mexican male. Oligonucleotide-SNP array analysis using the GeneChip Human Cytoscan HD was carried out for the patient from genomic DNA. The SNP array showed a 14.2-Mb deletion in chromosome 11q23.3q25 (120,706-134,938 Mb), which involved 163 RefSeq genes in the database of genomic variation. We report a novel deletion in JBS that increases the knowledge of the variability in the mutation sites in this region and expands the spectrum of molecular and clinical defects in this syndrome.

21 April 2014 in Current Eye Research
Verified
Journal Article
Closed access
PDF file
OBOlga Messina Baas
Olga Messina Baas
GCGuillermo Pacheco Cuellar
Guillermo Pacheco Cuellar
JLJaime Toral López
Jaime Toral López
SHSilvia Fanny Lara Huerta
Silvia Fanny Lara Huerta
LGLuz María Gonzalez-Huerta
Luz María Gonzalez-Huerta
SCSergio A Cuevas-Covarrubias
Sergio A Cuevas-Covarrubias
Background: The β adrenergic receptors (ADRB) are expressed in the ciliary body and trabecular meshwork, structures involved in aqueous humor production and outflow, respectively. ADRB are members of the adrenergic family of G-protein-coupled receptors. Topic β blockers have a good local and systemic tolerance; they reduce the aqueous humor production and eye strain blocking the ADRB of the ciliary body and interfering with adenylate cyclase. However, the ocular hypotensive response is not the same in all patients and could be mediated by the polymorphisms of the ADRB genes. Materials and methods: Seventy-two healthy subjects were studied after treatment with topical betaxolol in both eyes. We analyzed ADRB1 and ADRB2 gene polymorphisms by PCR and automated DNA sequencing. Results: There was statistically significant difference between baseline intraocular pressure (IOP) and final IOP of both eyes (baseline IOP 16.2 ± 1.2 – follow-up IOP 13.6 ± 2.0 (mean difference–2.5 ± 1.3, p < 0.001). Gly389 had a higher baseline IOP than Arg389 (17.0 ± 1.2 mmHg versus 16.0 ± 1.2 mmHg; p = 0.02), and conversely Arg389 had a greater magnitude of response than Gly389 to betaxolol therapy (−2.9 ± 1.1 mmHg versus −0.7 ± 0.4 mmHg; p < 0.001). Gln27 had a higher response than Glu27 (−2.7 ± 1.3 mmHg versus −1.9 ± 1.0; p = 0.02). Conclusion: Arg389 polymorphism of the ADRB1 gene and Gln27 polymorphism of the ADRB2 gene were associated with the hypotensive response to topic betaxolol in healthy Mexican volunteers.